Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Basilea Pharmaceutica Ltd
Basilea Pharmaceutica Ltd
Activities:
Research & Development
X
LinkedIn
Trending Articles
AbbVie and Gedeon Richter join forces to advance neuropsychiatric target R&D
The companies will aim to discover and progress targets for neuropsychiatric disorders
Containment in a high potent manufacturing facility
Throughout the pharmaceutical industry, there is a lack of consistency regarding the assignment of Occupational Exposure Limits (OELs) to specific bands
Rousselot
Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global...
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Causes and solutions for dark spots in tablet manufacturing
Natoli Engineering examines the causes and solutions for dark spots that can halt production
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Spexis sells preclinical antibiotics programme to Basilea
The CHF 2m deal gives Basilea ownership of a novel programme of Gram-negative bacteria-targeting antibiotics
Finance
Spexis announces sale of preclinical antibiotics programme to Basilea
Basilea to pay up to CHF2m for a preclinical programme with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains
Research & Development
Forge and Basilea partner on antibiotic discovery
Forge Therapeutics’s platform will be used by Basilea Pharmaceutica to develop inhibitors against two historically difficult-to-drug, unexploited antibiotic targets
Research & Development
Basilea awarded up to US$100m contract from BARDA
To advance clinical Phase III programme for ceftobiprole antibiotic
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Latest EU drug approvals span range of health issues
Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
Research & Development
Basilea's Chief Technology Officer to retire
Dr Günter Ditzinger named as successor Dr Ingrid Heinze-Krauss
Research & Development
Consortium signs deal with Basilea to develop targeted cancer therapy
Clinical Phase I testing of panRAF kinase inhibitors is expected to start this year
Subscribe now